Alan Pestronk focuses on Pathology, Immunology, Amyotrophic lateral sclerosis, Internal medicine and Antibody. Pathology connects with themes related to Muscle weakness in his study. His Immunology study frequently draws connections between related disciplines such as Weakness.
His work in the fields of Amyotrophic lateral sclerosis, such as Lower motor neuron, intersects with other areas such as Motor conduction block. His research integrates issues of Endocrinology and Surgery in his study of Internal medicine. The concepts of his Antibody study are interwoven with issues in Polyneuropathy and Ganglioside.
Alan Pestronk mainly focuses on Internal medicine, Pathology, Immunology, Antibody and Myopathy. He has researched Internal medicine in several fields, including Gastroenterology, Endocrinology and Surgery. As a member of one scientific family, Alan Pestronk mostly works in the field of Pathology, focusing on Weakness and, on occasion, Creatine kinase and Biopsy.
His Antibody study integrates concerns from other disciplines, such as Polyneuropathy and Ganglioside. His Myopathy research incorporates themes from Molecular biology and Hereditary inclusion body myopathy. His research in Amyotrophic lateral sclerosis intersects with topics in Genetics and Motor neuron.
Alan Pestronk spends much of his time researching Internal medicine, Pathology, Myopathy, Dysferlinopathy and Disease. While the research belongs to areas of Internal medicine, Alan Pestronk spends his time largely on the problem of Gastroenterology, intersecting his research to questions surrounding Nerve fiber. His Pathology study frequently draws connections to other fields, such as Weakness.
His Myopathy research integrates issues from Exome sequencing, Exome, Distal Myopathies and Hereditary inclusion body myopathy. His Amyotrophic lateral sclerosis research is multidisciplinary, incorporating perspectives in Genetics, Oncology and Missense mutation. His Antibody study is concerned with the larger field of Immunology.
Alan Pestronk mostly deals with Muscular dystrophy, Genetics, Amyotrophic lateral sclerosis, Pathology and Internal medicine. Alan Pestronk combines subjects such as Duchenne muscular dystrophy and Disease with his study of Muscular dystrophy. His Amyotrophic lateral sclerosis study combines topics in areas such as Missense mutation, Clinical trial, Tolerability, Age of onset and C9orf72.
His study in Pathology is interdisciplinary in nature, drawing from both Skeletal muscle, Magnetic resonance neurography and Polyradiculoneuropathy. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Physical therapy. He interconnects Myasthenia gravis, Immunology, Odds ratio, Case-control study and Single-nucleotide polymorphism in the investigation of issues within Cohort.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.
Giles D J Watts;Jill Wymer;Margaret J Kovach;Sarju G Mehta.
Nature Genetics (2004)
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS
Hong Joo Kim;Nam Chul Kim;Yong Dong Wang;Emily A. Scarborough.
Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis
Jeffrey D. Rothstein;Guochuan Tsai;Ralph W. Kuncl;Lora Clawson.
Annals of Neurology (1990)
A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.
A. Pestronk;D. R. Cornblath;A. A. Ilyas;H. Baba.
Annals of Neurology (1988)
TDP-43 A315T mutation in familial motor neuron disease.
Michael A. Gitcho;Robert H. Baloh;Sumi Chakraverty;Kevin Mayo.
Annals of Neurology (2008)
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
Ans T. van der Ploeg;Paula R. Clemens;Deyanira Corzo;Diana M. Escolar.
The New England Journal of Medicine (2010)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study
Timothy M Miller;Alan Pestronk;William David;Jeffrey Rothstein.
Lancet Neurology (2013)
A Phase I/II trial of MYO-029 in Adult Subjects with Muscular Dystrophy
Kathryn R. Wagner;James L. Fleckenstein;Anthony A. Amato;Richard J. Barohn.
Annals of Neurology (2008)
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
K V Toyka;D B Drachman;D E Griffin;A Pestronk.
The New England Journal of Medicine (1977)
Myasthenia gravis: passive transfer from man to mouse.
Klaus V. Toyka;Daniel B. Brachman;Alan Pestronk;Ing Kao.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: